Catherine Lee, MD
Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also leads the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials. Furthermore, she leads the Chronic Graft-versus-Host Disease/Long-Term Follow-Up Program for patients who have received hematopoietic cell transplantation. This program is designed to monitor the health and quality of life of patients after transplant, and also provides medical care specific to patients with chronic GVHD and late effects of hematopoietic cell transplantation. She is an active member of the American Society for Transplantation and Cellular Therapy (ASTCT), ASTCT Survivorship Special Interest Group, BMT CTN Steering Committee Member of the Toxicity and Supportive Care Committee, and the National Marrow Donor Program/Be The Match member of the Featured Trial Review Committee for the Jason Carter Clinical Trials Search and Support (CTSS).
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Incyte CorporationTopic:Research FundingDate added:09/29/2021Date updated:07/27/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KiteTopic:Advisory BoardDate added:09/29/2021Date updated:07/27/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Fresenius KabiTopic:ConsultantDate added:09/29/2021Date updated:07/27/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Jazz PharmaceuticalsTopic:Advisory Board, ConsultantDate added:09/29/2021Date updated:07/27/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KadmonTopic:Advisory BoardDate added:09/29/2021Date updated:07/27/2022
-
Attribution:Spouse or PartnerType of financial relationship:StockIneligible company:KadmonDate added:09/29/2021Date updated:07/27/2022